• Search

Discovery Stems From Here   

Find your tools for building human cell-based models & screening assays

Welcome to Axol Bioscience


We provide highly validated human iPSC-derived cells and primary cells from healthy donors and patients of specific disease backgrounds, together with optimized media and growth supplements. Axol aims to develop the best human cell biology research tools to advance medical research and drug discovery. Combining our passion for science with quality, innovation and customer service, we deliver robust and reliable products that our customers need to advance their research faster.

Latest News

  • Axol Bioscience appoints Liam Taylor as Chief Executive Officer

    Cambridge, UK, 26 August 2020: Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced the appointment of Liam Taylor as CEO. Liam will guide the growth of the Company, and will focus on maximizing the potential of the team, and its iPSC (induced pluripotent stem cell) technologies, products and services.

  • Chief Operating Officer appointed at Axol Bioscience

    We are delighted to announce that Chris Kirton joins us as our Chief Operating Officer; a senior operations leader with over 15 years of drug development, commercial and operational management experience in both industry and academia. Chris joins us from a leading supplier in the biotech industry and takes up his leadership role at Axol, bringing with him his extensive operational experience at the highest levels, focusing Axol's position and supporting growth within the Human iPSC-Derived Stem Cell market.

  • Major success for MESO-BRAIN partners will lead to breakthrough technology for developing new brain models

  • Neuroimmunology Drug Development (NIDD) 2019

    Our Booth #760
    Our Workshop (find out more)
    Our Poster (find out more)

  • Axol Bioscience launch human iPSC-derived Microglia

    Cambridge, UK – (6th December 2018) – Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.